Equities analysts forecast that Amgen, Inc. (NASDAQ:AMGN) will post earnings per share of $3.21 for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Amgen’s earnings. The highest EPS estimate is $3.42 and the lowest is $3.03. Amgen posted earnings of $3.15 per share in the same quarter last year, which would suggest a positive year over year growth rate of 1.9%. The business is expected to issue its next earnings results on Wednesday, April 25th.
According to Zacks, analysts expect that Amgen will report full-year earnings of $13.25 per share for the current financial year, with EPS estimates ranging from $12.71 to $14.23. For the next fiscal year, analysts forecast that the firm will post earnings of $13.83 per share, with EPS estimates ranging from $12.70 to $14.45. Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Amgen.
Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.84 billion. During the same period in the previous year, the firm earned $2.89 EPS. Amgen’s revenue for the quarter was down 2.7% on a year-over-year basis.
Shares of Amgen stock traded down $5.51 during trading hours on Thursday, reaching $176.08. The company had a trading volume of 3,521,314 shares, compared to its average volume of 5,319,167. Amgen has a 1 year low of $152.16 and a 1 year high of $201.23. The company has a market capitalization of $131,163.94, a PE ratio of 68.51, a price-to-earnings-growth ratio of 2.23 and a beta of 1.37. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49.
Amgen declared that its board has authorized a stock repurchase program on Thursday, February 1st that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be given a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a yield of 3.00%. The ex-dividend date is Wednesday, May 16th. Amgen’s payout ratio is 205.45%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 4,575 shares of company stock worth $838,064. Corporate insiders own 0.19% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of AMGN. Baker Ellis Asset Management LLC acquired a new stake in shares of Amgen during the 3rd quarter valued at $108,000. Phocas Financial Corp. acquired a new stake in shares of Amgen during the 2nd quarter valued at $110,000. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Amgen by 0.8% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after buying an additional 5 shares during the period. Barrow Hanley Mewhinney & Strauss LLC boosted its stake in shares of Amgen by 110.7% during the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 647 shares of the medical research company’s stock valued at $113,000 after buying an additional 340 shares during the period. Finally, Omnia Family Wealth LLC boosted its stake in shares of Amgen by 25.3% during the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after buying an additional 147 shares during the period. Hedge funds and other institutional investors own 79.50% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “$3.21 Earnings Per Share Expected for Amgen, Inc. (AMGN) This Quarter” was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://weekherald.com/2018/03/22/3-21-earnings-per-share-expected-for-amgen-inc-amgn-this-quarter.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.